Sodium phenylbutyrate is a medication that alters the breakdown of waste products in the liver. It is used to treat urea cycle disorders, primarily involving deficiencies or defects of the liver enzyme that removes ammonia from the blood. It works by enabling alternative pathways for the removal of nitrogen from the blood in patients with urea cycle disorders, which reduces ammonia accumulation.
The global sodium phenylbutyrate market is estimated to be valued at US$ 1.92 Billion in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The opportunity to treat urea cycle disorders presents a major market opportunity for sodium phenylbutyrate. Urea cycle disorders are a group of rare, inherited metabolic disorders caused by genetic defects that affect the urea cycle, which is crucial for removing ammonia from the blood. Left untreated, urea cycle disorders can cause dangerously high levels of ammonia in the blood, leading to neurological complications or even death. Currently, sodium phenylbutyrate is one of the only medication options available for the treatment of urea cycle disorders. With no cure available and a rising diagnosis rate, the treatment market for sodium phenylbutyrate is expected to witness significant growth over the forecast period. Additionally, ongoing research into newer delivery methods and therapeutics for urea cycle disorders indicates further growth prospects for sodium phenylbutyrate.
Porter's Analysis
Threat of new entrants: Low capital requirements however presence of established players limits opportunities.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of substitutes.
Bargaining power of suppliers: Few suppliers restricts their bargaining power.
Threat of new substitutes: Substitutes like hexylene glycol limits threat.
Competitive rivalry: Intense competition between major players influences pricing.
SWOT Analysis
Strength: Wide applications in fragrances, food and pharmaceutical industries. Effective medicine for certain rare diseases.
Weakness: High manufacturing cost and supply constraints. Toxic if consumed in high quantities.
Opportunity: Increasing demand for fragrances and personal care products in emerging markets. Potential in livestock feed.
Threats: Stringent regulation over manufacturing. Adverse publicity regarding synthetic chemicals.
Key Takeaways
The Global Sodium Phenylbutyrate Market Demand is expected to witness high growth over the forecast period of 2023 to 2030 supported by growing prevalence of rare urea cycle disorders and increasing adoption.
Regionally, North America dominates the global market and is estimated to maintain its lead over the forecast period. The growth in the region is driven by presence of major players and increasing healthcare expenditure. Europe is another prominent region in the global market supported by growing pharmaceutical industry in the region. Rising awareness about orphan drugs for rare diseases also drives the Europe market. The Asia Pacific market is expected to grow at a notable pace during the forecast period on back of expanding middle class population, rapid urbanization and rising healthcare spending in the region.
Key players operating in the sodium phenylbutyrate market are Procter & Gamble (P&G) Chemicals, CREMER, Wilmar, VVF Ltd., KLK OLEO, Inoue Perfumery MFG, Wuhan Yuancheng Gongchuang, Changsha Jianglong Chemicals, Godrej Industries. Major companies are engaged in new product launches and strategic collaborations to strengthen their position in the market.
Explore more information on this topic, Please visit @ https://www.rapidwebwire.com/by-increasing-hereditary-urea-cycle-disorders-prevalence-growth/
Comments
0 comment